Regenxbio Presents New Data on Investigational AAV Therapeutic for Retinal Conditions

At the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, new data was presented for Regenxbio's ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other additional chronic retinal conditions.

Mark Barakat, MD, and Arshad Khanani MD, MA, presented 1-year results from dose levels 1 and 2 of the phase 2 ALTITUDE trial of ABBV-RGX-314, the investigational gene therapy for DR.  

Key takeaways:  

• ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events 
• Dose level 2 prevented disease progression and reduced vision-threatening events in non-proliferative diabetic retinopathy patients at 1 Year
• 70.8% of patients achieved Diabetic Retinopathy Severity Scale improvement vs. 25.0 % in control
• 0% of patients worsened ≥ 2 steps vs. 37.5 % in control
• ABBV-RGX-314 reduced vision-threatening events by 89% compared to control 

The presentation can be found here.